Viewing nowSimvarol Tablet (Simvastatin)
Simvastatin 20mg
Tablet · Prescription medication
Youngil Pharmaceutical Co., Ltd.

MFDS item code 200402309 · Notified 2004.06.23 · Insurance code 649401280
Improves hyperlipidemia (including pediatric familial hyperlipidemia) and reduces the risk of cardiovascular disease
This medication is used to reduce the risk of cardiovascular diseases. It helps lower the risk of heart-related death and the occurrence of myocardial infarction and stroke in adult patients with a history of coronary heart disease, diabetes, peripheral vascular disease, or stroke. It also contributes to reducing risk after angioplasty. It is effective in treating hyperlipidemia, managing cholesterol and triglyceride levels in patients with familial and non-familial hypercholesterolemia and mixed dyslipidemia, thus improving blood lipid status. It is also used in pediatric patients with familial hypercholesterolemia to assist with dietary measures in lowering cholesterol levels. Therefore, this medication is actively used for the prevention of cardiovascular diseases and improvement of hyperlipidemia.
Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. 1. Reduction of the risk of cardiovascular disease Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this drug once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this drug. The recommended dose is 5 ~ 40 mg of this drug once daily in the evening. Adjust the dose as appropriate according to the initial LDL cholesterol level before starting treatment, the treatment target, and the patient's response to the drug. Measure cholesterol levels 4 weeks after starting treatment and regularly thereafter to adjust the dose. Reduce the dose if cholesterol levels fall below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of this drug at a dose of 80 mg, particularly during the first year of treatment, should be limited to patients who have taken 80 mg of this drug for 12 months or longer without evidence of muscle toxicity (see 1. Warnings in Precautions for Use). 2) For recommended doses in patients receiving this drug concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, older adults, and patients with renal impairment), see below (see 6. Interactions in Precautions for Use). (1) Use in patients with homozygous familial hypercholesterolemia Controlled clinical trial results show that patients with homozygous familial hypercholesterolemia should receive 40 mg of this drug once daily in the evening. Administer this drug in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In older adults, a daily dose of 20 mg of this drug may achieve the maximum cholesterol-lowering effect. (3) Use in patients receiving verapamil, diltiazem, or dronedarone When this drug is coadministered with verapamil, diltiazem, or dronedarone, the dose of this drug should not exceed 10 mg per day. (4) Use in patients receiving amiodarone, amlodipine, or ranolazine When this drug is coadministered with amiodarone, amlodipine, or ranolazine, the dose of this drug should not exceed 20 mg per day. (5) Concomitant use with other lipid-lowering agents This drug is effective when administered alone or in combination with a bile acid sequestrant. When this drug is coadministered with a fibrate (excluding gemfibrozil (see 2. Patients in Whom the Drug Must Not Be Administered in Precautions for Use) and fenofibrate), the dose of this drug should not exceed 10 mg per day. (6) Use in patients with renal impairment Because this drug is not extensively excreted by the kidneys, no dosage adjustment is needed in patients with mild to moderate renal impairment. In patients with severe renal impairment, however, start with an initial dose of 5 mg per day and monitor carefully.
Pediatric patients (10 ~ 17 years) with heterozygous familial hypercholesterolemia: The recommended initial dose is 10 mg of this drug once daily in the evening. The recommended dose range is 10 ~ 40 mg per day, and the recommended maximum dose is 40 mg per day. Adjust the dose appropriately for each patient according to the recommended treatment target. Allow an interval of 4 weeks or longer between dose adjustments.
This medication can cause serious muscle-related side effects such as myopathy and rhabdomyolysis, which are closely related to the dosage taken. Patients on an 80 mg dose have a higher risk of myopathy, so it is advisable to reduce the dosage or switch to another medication when taking other drugs that interact with this medication. Patients with allergies to this medication or its components, patients with severely impaired liver function, women who are pregnant or nursing, patients taking strong CYP3A4 inhibitors, and those taking specific medications (gemfibrozil, cyclosporine, danazol) should not use this medication. Patients with certain genetic disorders such as lactose intolerance should also avoid this medication. Alcoholics, patients with liver or kidney dysfunction, patients with hypothyroidism, those with hereditary muscle diseases or a history of muscle-related conditions, patients with severe muscle weakness, older adults, and women should use this medication with caution. This medication can cause various side effects such as edema, abdominal pain, constipation, headache, and upper respiratory infections, and immediate consultation with a physician is recommended if symptoms such as muscle pain or weakness occur. Since this drug is primarily metabolized by the liver, patients with liver dysfunction should undergo regular liver function tests and discontinue use if symptoms of liver impairment appear. Additionally, this medication can interact with several drugs, so it is crucial to inform healthcare providers about any other medications being taken, particularly if combined with CYP3A4 inhibitors, fibrates, calcium channel blockers, niacin, certain antibiotics, and antivirals. Women who are pregnant or likely to become pregnant should not take this medication, and if pregnancy is confirmed, they should discontinue use immediately. Nursing mothers should also stop breastfeeding while taking this medication. This medication should not be given to children under 10 years old or premenarchal females, and children over 10 years should take it according to a physician’s instructions. Older adults may have increased blood levels of this medication, leading to a higher risk of myopathy, requiring dosage adjustment and caution. If symptoms like muscle pain, weakness, or tenderness arise during treatment, it is advised to promptly inform a physician and regularly check muscle enzyme levels through blood tests. Patients taking this medication should avoid CYP3A4 inhibiting drinks like grapefruit juice, and in case of overdose, should seek immediate medical assistance. Keep out of reach of children and store the medication in its original container to prevent misuse and degradation of quality.
Myopathy, rhabdomyolysis, abdominal pain, weakness, constipation, diarrhea, dyspepsia, bloating, nausea, headache, upper respiratory tract infection, edema, atrial fibrillation, gastritis, diabetes, myalgia, insomnia, dizziness, bronchitis, sinusitis, eczema, urinary tract infection, muscle cramps, arthralgia, immune-mediated necrotizing myopathy, specific cranial nerve dysfunction, tremor, sensory disturbances, peripheral neuropathy, peripheral nerve paralysis, mental disorders, anxiety, sleep disturbances, depression, cognitive impairment, myasthenia gravis, ocular myasthenia gravis, hepatitis, liver dysfunction, jaundice, alopecia, pruritus, skin changes, lichenoid drug eruption, gynecomastia, decreased libido, sexual dysfunction, cataract progression, ocular muscle paralysis, anemia, elevated aminotransferases, elevated ALP, elevated γ-GTP, elevated bilirubin levels, thyroid dysfunction, elevated serum creatine kinase, abnormal liver function tests, diabetes, liver failure, pancreatitis, cholestatic jaundice, hepatic fatty change, cirrhosis, fulminant liver necrosis, liver cancer, appetite loss, vomiting, mucocutaneous syndrome, urticaria, phototoxicity, fever, chills, flushing, lethargy, dyspnea, toxic epidermal necrolysis, thrombocytopenia, leukopenia, hemolytic anemia, positive antinuclear antibodies, increased erythrocyte sedimentation rate, eosinophilia, arthritis, vasculitis, purpura, lupus-like syndrome, polymyositis, dermatomyositis, angioedema, anaphylaxis, interstitial lung disease, limb sensory numbness, tingling, cold sensation, peripheral nerve disorders, thrombocytopenia, interstitial lung disease, cataract, optic nerve degeneration, vestibular cochlear Wallerian-like degeneration, retinal ganglion cell chromatolysis, perivascular hemorrhage, perivascular edema, perivascular mononuclear cell infiltration, perivascular fibrin deposition, small vessel necrosis, vomiting, mucous stools
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should ideally remain between 1 to 30 degrees Celsius at room temperature, which will help maintain the efficacy of the medication.
Brownish-yellow oval film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSimvastatin 20mg
Tablet · Prescription medication
Youngil Pharmaceutical Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Jongkundang Pharmaceutical Co., Ltd.
Simvastatin 20mg
Tablet · Prescription medication
Dong-A ST Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Korea Hutech Pharmaceutical Co., Ltd.
Simvastatin 20mg
Tablet · Prescription medication
Yuhan Corporation

Simvastatin 40mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Dongsung Pharmaceutical Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
HK inno.N Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.